norepinephrine in the synaptic cleft. Studies show it takes 2-3 weeks for the mood-enhancing effects, which indicates other mechanisms may underlie their treatment effects. Here, we investigated the role of white matter in treatment and pathogenesis of depression using an unpredictable chronic mild stress (UCMS) mouse model. Methods: Desvenlafaxine (DVS) was orally administrated to UCMS mice at the dose of 10mg/kg/day one week before they went through 7 weeks stress procedure and lasted for over 8 weeks before the mice being sacrificed. Results: No significant changes were found for protein markers of neurons and astrocytes in UCMS mice. However, myelin and oligodendrocyte related proteins were significantly reduced in UCMS mice. DVS prevented the stress-induced injury to white matter and the decrease of phosphorylated 5'-AMP-activated protein kinase (AMPK-α) and 3-hydroxy-3-methyl-glutarylCoA reductase (HMG-CoA reductase) protein expression. DVS increased open arm entries in elevated plus maze, sucrose consumption in sucrose preference test and decreased immobility in tail suspension and forced swimming tests. Summary: These findings suggest stress induces depressionlike behaviors and white matter deficits in UCMS mice. DVS may ameliorate the oligodendrocyte dysfunction by affecting cholesterol synthesis, alleviating the depression-like phenotypes in these mice.
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Single administration of ketamine and Pregnenolone-Methyl-Ether (3ß-Methoxy-Pregnenolone) has antidepressant efficacy in a preclinical model of treatment resistant depression: identification of a plasma biomarker of pharmacological efficacy Jack Prenderville, Massimiliano Bianchi, Grazia Di Capua, Conor McDonnell, Jennifer Rouine Transpharmation Ireland, Trinity College Dublin, Ireland Abstract Objective: One third of major depressive disorder (MDD) patients are unresponsive to antidepressant drugs, a sub-type known as treatment resistant depression (TRD). Acute intravenous administration of ketamine at sub-anaesthetic dosage is the only efficacious pharmacological treatment in TRD. Development of TRD preclinical assays to screen for more efficacious antidepressant drugs and identification of diagnostic biomarkers is therefore of immediate importance. The neuronal microtubule modulator Pregnenolone-Methyl-Ether (PME; also known as 3β-MethoxyPregnenolone) has been shown to have antidepressant efficacy. Methods: The Wistar Kyoto (WKY) rat was used as a model of TRD to investigate the effectiveness of fluoxetine (10mg/kg, i.p.), ketamine (5mg/kg, i.p.) and PME (10mg/kg, s.c.) in the forced swimming test (FST). Hippocampal acetylated α-tubulin (Acet-Tub) was previously shown increased in preclinical models of depression and was here investigated as a potential plasma biomarker. Results: WKY rats demonstrated depressive-like behaviour indicated by increased immobility in the FST associated with overexpression of plasma Acet-Tub compared to Sprague Dawley rats. Acute treatment with the selective serotonin inhibitor (SSRI) fluoxetine had no effect on FST immobility but increased plasma Acet-Tub in WKY rats. Acute administration of ketamine or PME demonstrated rapid antidepressant efficacy in the FST with the effects of ketamine persisting for 7 days. Ketamine and PME demonstrated long-lasting antidepressant efficacy in the FST 24h post-administration. Furthermore, both drugs decreased plasma Acet-Tub overexpression only when their antidepressant efficacy was evident. Conclusion: WKY rats are a suitable model for screening of novel pharmacological treatments for TRD due to their sensitivity to ketamine and lack thereof to SSRIs. PME demonstrates antidepressant efficacy in this model of TRD while plasma AcetTub represents a potential biomarker of disease progression and pharmacological efficacy. Therefore, microtubules represent a potential target for future drug development in TRD.
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Effect of pramipexole for learned helplessness behavior and cranial nerve activities In recent years, research has been reported that dopamine agonists used in the treatment of Parkinson's disease have also shown effectiveness in treating patients for depression. We treated animals with the pramipexole (PRM) and observed behavioral changes and changes in the function of the cranial nerves in animal models of learned helplessness. The purpose of the experiment is to investigate the dopamine agonist's effect as an antidepressant for depressive states as well as its role regarding the cranial nerves.
Method:
The experiment included a learned helplessness behavior test, and an assessment of the cranial nerve function using c-Fos immunohistochemistry staining. The learned helplessness model involved a 5-day protocol. The drug was given for four consecutive days, and on the fifth day we measured the number of failed escape attempts using the same method as the second day. The increase or decrease in number of escape attempts was used as an indicator of the drug's effectiveness. In order to examine the effect of PRM on cranial nerve activities in learned helplessness, after completion of the test on the fifth day, the brains were collected and any changes to nerve function in the nucleus accumbens, amygdala and hippocampus were assessed using c-Fos immunohistochemistry staining.
Results and Observations:
In learned helplessness models given a single dose of PRM (1.0mg/kg, i.p.), a significant decrease was observed in the number of failed escape attempts related to learned helplessness behavior. This therefore suggests that PRM, in addition to improving Parkinson's symptoms, is a drug that also has antidepressant effects. Furthermore, regarding the parts of the brain affected by PRM's antidepressant function, the nerves of the nucleus accumbens shell, central nucleus and basolateral of the amygdala, and dentate gyrus and CA3 regions of the hippocampus were shown to be affected by the antidepressant function.
